Ran Frenkel
2021
In 2021, Ran Frenkel earned a total compensation of $1.6M as Executive Vice President, Chief Development Officer at Karyopharm Therapeutics.
Compensation breakdown
| Bonus | $50,000 |
|---|---|
| Non-Equity Incentive Plan | $172,000 |
| Option Awards | $588,826 |
| Salary | $429,525 |
| Stock Awards | $320,509 |
| Other | $16,343 |
| Total | $1,577,203 |
Frenkel received $588.8K in option awards, accounting for 37% of the total pay in 2021.
Frenkel also received $50K in bonus, $172K in non-equity incentive plan, $429.5K in salary, $320.5K in stock awards and $16.3K in other compensation.
Rankings
In 2021, Ran Frenkel's compensation ranked 7,049th out of 12,415 executives tracked by ExecPay. In other words, Frenkel earned more than 43.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,049 out of 12,415 | 43rd |
Division Manufacturing | 3,086 out of 5,505 | 44th |
Major group Chemicals And Allied Products | 1,365 out of 2,375 | 43rd |
Industry group Drugs | 1,215 out of 2,096 | 42nd |
Industry Pharmaceutical Preparations | 887 out of 1,546 | 43rd |
Source: SEC filing on April 8, 2022.
Frenkel's colleagues
We found five more compensation records of executives who worked with Ran Frenkel at Karyopharm Therapeutics in 2021.
2021
Richard Paulson
Karyopharm Therapeutics
Chief Executive Officer
2021
Sharon Shacham
Karyopharm Therapeutics
Chief Scientific Officer
2021
Michael Kauffman
Karyopharm Therapeutics
Chief Executive Officer
2021
Michael Mason
Karyopharm Therapeutics
Chief Financial Officer
2021
Jatin Shah
Karyopharm Therapeutics